To determine the combined effects and mechanisms of the CXCR4 blockade by LY2510294 with FLT3 inhibitors, we next tested whether CXCR4 inhibition by LY2510924 could overcome stroma-mediated protection against quizartinib in FLT3-ITD mutated AML cells in vitro by co-culturing MOLM-14 cells with MS-5 stromal cells or hMSC from FLT3-ITD-AML (Table S1) for three days. This evidence concerns the gene CXCR4 and acute myeloid leukemia.